Blood tests Vs Poop tests...1) EXAS:US...
August , 2018 Pfizer and EXAS:US signed a deal, Pfizer will promote and sell EXAS:US Cologuard tests ( a poop test).
This deal indicate that Pfizer is serious about enlarging its cancer testing portfolio.
PS: EXAS:US $75.00 USD ($97.00 CAD) is almost exclusively supported by the expected proceed of one single poop cancer test (Cologuard).
2) LifeX...
Strange coincidence that LifeX who has very good contacts with Pfizer came on board (August, 2018) almost at the same time that Pfizer is showing growing interests in cancer testing potential.
Look like somebody want a piece of the cake...no problem its a very big cake, with 4 cancer tests ready for market, and more to come its a billions dollard cake, Aristotle will be icing on the cake (worth billions by itself).
3) Accuracy...
Genenews blood cancer tests are more accurate for detecting cancer...up to 2 years earlier than other methods, and cost much less than a CT scan.
4) Partnership...
The more you look at it, the more you realize that the new partnerships developed lately by Jame Tripp (AIM Laboratories, LifeX, JTS ) will have a big impact on Genenews.
5) Billions $...
Genenews, AIM Laboratories and Lifex have access to innovative blood tests technologies with billions dollard potential.
Hold on to your shares, relax and enjoy the ride.